

ASX Announcement



Medibio Limited – 24 June 2020

MEB Announces Extension to Entitlement Offer

Melbourne, Australia and Minneapolis, MN – 24 June 2020: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), a health technology Company advises that due to delayed delivery of offer letters via Australia Post services and to allow eligible shareholders additional time to consider the offer the Closing Date for the Non-Renounceable Entitlement Offer will be extended to 5:00pm (AEST) 6 July 2020. The revised indicative timetable is set out below.

Event	Date
Entitlement Offer Closing Date	5.00pm Monday, 6 July 2020
Announcement of results of Entitlement Offer	Thursday, 9 July 2020
Issue shares and lodge Appendix 2A	Monday, 13 July 2020
Shares commence trading on a regular basis	Tuesday, 14 July 2020

**The above timetable is indicative only and subject to change. The quotation of New Shares is subject to ASX approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserves the right to vary these dates, without notice. Any extension of the Entitlement Offer will have a consequential effect on the issue date of the New Shares.*

How to Accept the Offer

The Company also reminds Eligible Shareholders who wish to subscribe to the offer they can **only** do so by entering your personal details (including your SRN/HIN and postcode) at the following link: <https://medibio2020offer.thereachagency.com>. Once completed please follow the instructions provided including making payment by BPAY® (for New Zealand or Hong Kong Shareholders only, that are unable to pay via BPAY®, please contact the Company Secretary on +61 3 9692 7222 for alternative EFT payment arrangements).

The amount you pay via BPAY® will be deemed to be your total subscription. If this amount is above your entitlement as set out in your personalised application form, these additional shares may be subject to a scale back. For further details on how to apply please refer to Section 4.10 of the Offer Document announced to the ASX on 10 June 2020.

– ENDS –

Mathew Watkins
Joint Company Secretary
Medibio Limited

For further information, please contact Mr Watkins on +61 3 9692 7222

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au
ACN: 008 130 336